FDA issued a Warning Letter to Sato Pharmaceutical Co., Ltd., a Japanese OTC drug manufacturer, on May 18, 2026.
I want to be direct about what this letter actually represents before we get into the specifics. This is not a Warning Letter for inadequate procedures or incomplete documentation. This is FDA telling a manufacturer that their sterile filling line is fundamentally unsuitable for sterile manufacturing.
Those are two different categories of finding. And they have two very different trajectories.
As an FDA Investigator, I conducted sterility-related inspections. When I read language like “fundamentally unsuitable for its intended use” in a Warning Letter, I know what that means operationally. It means FDA does not believe this facility can manufacture sterile drug products safely under current conditions. Not that they need to improve. That the foundation is wrong.
Here is what FDA found:
Six Media Fill Failures Over Two Years
Between November 2022 and February 2025, Sato’s attempts to validate their aseptic filling line resulted in at least six media fill failures.
For those unfamiliar with media fill operations: it is basically a simulation of a facility’s routine production process using open containers filled with growth media that captures any microbial contamination. It gives actual evidence of what is happening during production, from personnel habits to environmental integrity.
The airflow visualization studies made the situation worse. These are smoke studies that could not demonstrate what they were designed to demonstrate.
Stability Programs That Cannot Detect Degradation
A stability program is supposed to detect product degradation over time.
Products were distributed to the U.S. market with stability data that showed unidentified impurity peaks that were never evaluated for patient safety.
Sato manufactured and released OTC drug products to the U.S. market without conducting required microbiological testing.
They may still be on U.S. pharmacy shelves.
FDA required reserve sample testing, health hazard evaluations, patient risk assessment, and evaluation of the need for market action.
The vulnerabilities FDA found at Sato Pharmaceutical are not unique to one Japanese OTC manufacturer. Aseptic process design deficiencies that produce media fill failures exist at other facilities.
The full breakdown, including what FDA is really saying behind each finding and the specific actions your quality team should take right now, is in the paid edition of The Investigator’s Lens.
Read the full article here: https://open.substack.com/pub/devaughnedwards/p/sato-pharmaceutical-just-got-an-fda?r=7sflcx&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true
DeVaughn Edwards is a former FDA Investigator with 14 years of field experience, a pharmaceutical quality executive with 13 years of hands-on compliance leadership, and the founder of FD-AID LLC. He conducts mock FDA inspections and inspection readiness engagements for pharmaceutical manufacturers, CDMOs, and biologics facilities.
Contact: devaughn@fdaid.org | fdaid.org | 732-895-7831
FD-AID | FDA Inspection Readiness | Former FDA Investigator 